UY33225A - (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4 - Google Patents

(r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4

Info

Publication number
UY33225A
UY33225A UY0001033225A UY33225A UY33225A UY 33225 A UY33225 A UY 33225A UY 0001033225 A UY0001033225 A UY 0001033225A UY 33225 A UY33225 A UY 33225A UY 33225 A UY33225 A UY 33225A
Authority
UY
Uruguay
Prior art keywords
methyl
iloxi
piran
isoxazol
piperidin
Prior art date
Application number
UY0001033225A
Other languages
English (en)
Spanish (es)
Inventor
Noguchi Hirohide
Waizumi Nobuaki
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY33225A publication Critical patent/UY33225A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001033225A 2010-02-16 2011-02-14 (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4 UY33225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16

Publications (1)

Publication Number Publication Date
UY33225A true UY33225A (es) 2011-09-30

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033225A UY33225A (es) 2010-02-16 2011-02-14 (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4

Country Status (15)

Country Link
US (1) US20120041026A1 (instruction)
EP (1) EP2536713A1 (instruction)
JP (1) JP2013519722A (instruction)
KR (1) KR20120123089A (instruction)
CN (1) CN102762554A (instruction)
AR (1) AR080172A1 (instruction)
AU (1) AU2011216950A1 (instruction)
CA (1) CA2788656A1 (instruction)
IN (1) IN2012DN06631A (instruction)
MX (1) MX2012008721A (instruction)
SG (1) SG183111A1 (instruction)
TW (1) TW201141856A (instruction)
UY (1) UY33225A (instruction)
WO (1) WO2011101774A1 (instruction)
ZA (1) ZA201206469B (instruction)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA2836372C (en) * 2011-05-18 2020-09-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
WO2014080633A1 (en) * 2012-11-21 2014-05-30 Raqualia Pharma Inc. Polymorph forms
EA029365B1 (ru) 2013-03-20 2018-03-30 Сувен Лайф Сайенсиз Лимитед 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-htрецептора
CA2932428C (en) 2013-12-16 2017-10-24 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists
TWI672300B (zh) * 2014-05-20 2019-09-21 日商拉夸里亞創藥股份有限公司 苯并異唑衍生物鹽類
HRP20191179T1 (hr) 2015-02-13 2019-10-04 Suven Life Sciences Limited Spojevi amida kao agonisti 5-ht4 receptora
CN117796401A (zh) * 2023-12-25 2024-04-02 江苏万隆化学有限公司 一种含2-羟基-6-氟苯甲酸甲酯中间体抗菌剂的制备工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2104297C (en) 1991-02-27 2003-05-27 Boyd Lynn Harrison 4-sulfanimide-quinoline nmda antagonists
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
AU690529B2 (en) * 1992-11-23 1998-04-30 Hoechst Marion Roussel, Inc. Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
WO1997012870A1 (en) 1995-09-29 1997-04-10 Glaxo Wellcome S.P.A. Tetrahydroquinolines as nmda antagonists
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
ATE207483T1 (de) 1996-04-12 2001-11-15 Aventis Pharma Inc Isatinderivate als acetylcholinesterase- inhibitoren und analgetika
ES2179353T3 (es) 1996-07-01 2003-01-16 Schering Corp Antagonistas muscarinicos.
JP3390179B2 (ja) 1996-08-15 2003-03-24 シェーリング コーポレイション エーテルムスカリン様アンタゴニスト
KR20000048715A (ko) 1996-09-30 2000-07-25 게리 디. 스트리트, 스티븐 엘. 네스비트 Ｎｍｄａ (ｎ-메틸-ｄ-아스파르테이트) 길항제
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
ATE380172T1 (de) 2001-01-26 2007-12-15 Btg Int Ltd Benzylaminanalogen
CA2440284A1 (en) 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
SI1409477T1 (sl) 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
HRP20080490T3 (en) 2003-06-04 2008-11-30 Merck & Co. Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
SG10201400339VA (en) * 2004-03-03 2014-05-29 Revance Therapeutics Inc Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
MX2007004458A (es) 2004-10-15 2007-08-08 Univ Rio De Janeiro Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes.
WO2006090224A1 (en) 2005-02-25 2006-08-31 Pfizer Japan Inc. Benzisoxazole derivatives
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
US20090258824A1 (en) 2005-07-29 2009-10-15 Ashe Karen H Amyloid beta receptor and uses thereof
CN101437510B (zh) 2006-03-20 2012-12-05 科学与工业研究会 用作乙酰胆碱酯酶抑制剂的药物组合物
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
WO2008074816A1 (en) 2006-12-20 2008-06-26 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
DK2345653T3 (da) 2007-05-01 2013-04-08 Concert Pharmaceuticals Inc Morphinanforbindelser
GB2462235B8 (en) 2007-05-11 2013-03-27 Biotechnology Res Corp Ltd Receptor modulators exhibiting neuroprotective andmemory enhancing activities
AU2008272964A1 (en) 2007-06-29 2009-01-08 Emory University NMDA receptor antagonists for neuroprotection
CA2699412A1 (en) 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
WO2009092324A1 (en) 2008-01-16 2009-07-30 Hong Kong University Of Science And Technology Oxazolidine derivatives as nmda antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
BRPI0912362A2 (pt) 2008-05-09 2015-10-06 Univ Emory antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos

Also Published As

Publication number Publication date
US20120041026A1 (en) 2012-02-16
AU2011216950A1 (en) 2012-08-23
SG183111A1 (en) 2012-09-27
JP2013519722A (ja) 2013-05-30
WO2011101774A1 (en) 2011-08-25
EP2536713A1 (en) 2012-12-26
KR20120123089A (ko) 2012-11-07
CN102762554A (zh) 2012-10-31
ZA201206469B (en) 2013-05-29
MX2012008721A (es) 2012-08-17
AR080172A1 (es) 2012-03-21
TW201141856A (en) 2011-12-01
CA2788656A1 (en) 2011-08-25
IN2012DN06631A (instruction) 2015-10-23

Similar Documents

Publication Publication Date Title
UY33225A (es) (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4
HUS2200033I1 (hu) CGRP receptor antagonisták
PL2513093T3 (pl) Nowi antagoniści receptora CCR2 i ich zastosowanie
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
EA200870409A1 (ru) Антагонисты киназы pi3
EP2013169A4 (en) INDOLAMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
EP2083861A4 (en) Antagonists of pcsk9
EP2480576A4 (en) PCSK9 ANTAGONISTS
IL239604A0 (en) Anti-vegf antibodies and their uses
EP2218187A4 (en) MODIFYING THE OPERATION OF A MOBILE DEVICE USING PROXIMITY RELATIONSHIPS
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
EP2470173A4 (en) COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS FROM TAXAN AND HEDGEHOG HEMMERN
HRP20190016T1 (hr) Heterociklički spojevi i njihova upotreba
EP2083859A4 (en) ANTAGONISTS OF PCSK9
BR112013015374A2 (pt) sonda de vitrectomia com tamanho ajustável do orifício do cortador
PL2638042T3 (pl) Antagoniści receptorów CGRP w postaci piperydynonokarboksyamidu azaindanu
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
BRPI1012097A2 (pt) antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos.
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
BRPI0716841A2 (pt) benzoxazàis e oxazolopirindinas sendo puteis como inibidores de janus quinases
ATE539056T1 (de) Piperidinderivate als agonisten muskariner rezeptoren
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
DK2483505T3 (da) Balkonrækværk med integreret læskærm

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191216